Third Obesity Drug Wins FDA Okay
(MedPage Today) -- Following an earlier snub, the FDA finally approved the weight-loss drug Contrave, a combination of bupropion and naltrexone, the agency announced. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 11, 2014 Category: Cardiology Source Type: news
FDA Approves Bupropion/Naltrexone (Contrave) for ObesityFDA Approves Bupropion/Naltrexone (Contrave) for Obesity
After a rocky start, the FDA has finally approved the obesity medication, but with a boxed warning about the risk for suicidal thoughts and serious neuropsychiatric events. FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 11, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda
The FDA announced today that it had approved Contrave, the long-awaited and much-disputed weight loss drug. The drug is a combination of two drugs already approved for other indications: naltrexone hydrochloride, which is used to combat alcohol and opioid dependence, and bupropion, which is used to treat depression and seasonal affective disorder and as an aid to smoking cessation treatment. Contrave is manufactured by Orexigen and will be distributed by Takeda. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 10, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
FDA approves weight-management drug Contrave
The U.S. Food and Drug Administration today approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 10, 2014 Category: American Health Source Type: news
Intravenous administration and abuse of bupropion: a case report and a review of the literature - Oppek K, Koller G, Zwergal A, Pogarell O.
INTRODUCTION:: Bupropion is an effective and well-tolerated second-generation antidepressant generally assumed to be without abuse potential. In the past years, several case reports about the recreational use of bupropion, mainly via nasal insufflation, ha... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - August 8, 2014 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
More Evidence Drug Combo Helps Smokers QuitMore Evidence Drug Combo Helps Smokers Quit
The combination of varenicline and bupropion proves successful in an 'adaptive' smoking cessation paradigm. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2014 Category: Consumer Health News Tags: Psychiatry News Source Type: news
New Weight-Loss Drugs: When to Prescribe?New Weight-Loss Drugs: When to Prescribe?
Dr. Steven Smith reviews 2 weight-loss drugs in the pipeline, liraglutide and naltrexone/bupropion, and discusses how to prescribe such drugs and appropriate patients to receive them. Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
Three-Month Delay in US for Bupropion/Naltrexone for Obesity Three-Month Delay in US for Bupropion/Naltrexone for Obesity
The expected decision on bupropion/naltrexone for obesity has not materialized. Instead, the FDA has extended the review time by 3 months, with a decision now due in September. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Antidepressants differ in effect on weight gain
Less weight gain with bupropion, nortriptyline and amitriptyline than citalopramRelated items from OnMedicaOlder generation antidepressants linked to heart diseaseMental and physical healthcare should be integratedCommunity mental health service users left out of decisionsDepressed patients stick with phone CBTLithium cuts suicide risk in people with mood disorders (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 6, 2014 Category: UK Health Source Type: news
Hope on Horizon for Newer Obesity Drugs in Europe?Hope on Horizon for Newer Obesity Drugs in Europe?
The lack of obesity drugs in Europe was the focus of much discussion at the European Conference on Obesity last week. Hopes are high that bupropion/naltrexone and liraglutide will soon be approved there. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 4, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Good quick review of bupropion toxicity, but . . . whole bowel irrigation? Seriously??
2.5 out of 5 stars
Bupropion Abuse and Overdose. Stall N et al. CMAJ 2014 Apr 28 [Epub ahead of print]
No abstract available online
This one-page précis is part of CMAJ‘s “Five Things To Know About _______” series. The key points include:
Bupropion blocks reuptake of dopamine and norepinephrine, and also blocks the action of acetylcholine at nicotinic receptors.
Burpropion is abused recreationally for its mild cocaine-like “high.”
Routes of bupropion abuse include snorting, ingestion, and intravenous injection.
Brupropion lowers the threshold for seizures, which may be delayed as long as ...
Source: The Poison Review - May 9, 2014 Category: Toxicology Authors: Leon Tags: Medical abuse bupropion overdose seizures Source Type: news
Asystole shortly after intravenous fat emulsion for overdose: causation or coincidence?
3 out of 5 stars
Asystole Immediately Following Intravenous Fat Emulsion for Overdose. Cole JB et al. J Med Toxicol 2014 Feb 12. [Epub ahead of print]
Abstract
This case paper describes 2 patients who developed asystolic within 60 seconds of being given intravenous fat emulsion (IFE) bolus for treatment of severe cardiotoxicity. Both patients had return of spontaneous circulation (ROSC) after several minutes of cardiopulmonary resuscitation. Unfortunately, both patients died days after admission from multisystem organ failure.
Patient A, a 50-year-old woman, had ingested an undetermined about of metoprolol and bupropion...
Source: The Poison Review - February 18, 2014 Category: Toxicology Authors: Leon Tags: Medical asystole bupropion cardiac arrest diltiazem intralipid intravenous fat emulsion therapy metoprolol propranolol Source Type: news
bupropion, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Title: bupropion, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XLCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/22/2014 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - January 22, 2014 Category: Psychiatry Source Type: news
Zydus Cadila gets USFDA nod for anti-depressant drug
Drug major Zydus Cadila has received approval from the US health regulator to market Bupropion Hydrochloride extended-release tablets, an anti-depressant medicine, in the American market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 21, 2014 Category: Pharmaceuticals Source Type: news
Drug Combo Boosts Early Quit Rates in SmokersDrug Combo Boosts Early Quit Rates in Smokers
Combining varenicline with bupropion may boost early quit rates compared with varenicline alone; heavier smokers most likely to benefit. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - January 9, 2014 Category: Psychiatry Tags: Psychiatry News Source Type: news
